Cytokinetics Wins Non-Obstructive HCM, Stock Falls Anyway & Teva bids $57.5M for BioXcel asset as shares collapse 66%

Cytokinetics won a trial nobody had ever won before this morning — and the market took a chunk out of the stock anyway.

Moderna borrowed two point six billion dollars for its cancer work, BioNTech and Genentech killed a Phase 2 cancer vaccine over a survival imbalance, and Teva is bidding for BioXcel's neuroscience asset out of bankruptcy court. It's been a loud Friday. Let's get into it.

Welcome to The Pharma Closeout for Friday, August 28th. I'm Alex Mercer.

And I'm Maya Patel.

So, Cytokinetics — the gap between what the data says and what the tape says is the story.

That's the tell.

And it isn't irrational. In obstructive disease you had a gradient to knock down — a mechanical target, a mechanical readout, a number that moves and everyone agrees it moved. Non-obstructive gives you neither. Normal ejection fraction, real symptom burden, and no lever with a dial on it. Cytokinetics' chief medical officer called ACACIA the first-ever positive clinical trial in non-obstructive HCM, and I'd accept that framing — nobody has cleared this before. But the question the tape is asking isn't whether it cleared. It's whether it cleared by enough to change what a cardiologist does on Monday morning.

So let's put the number on the table. On the Kansas City symptom score, aficamten beat placebo by three points — eleven point four versus eight point four from baseline, p equals zero point zero two one. It got there. It got there by a hair.

Say the placebo number again.

Eight point four.

That's what I'd stress. A placebo arm gaining eight point four points on a patient-reported instrument is a very large response, and it squeezed the treatment difference into a confidence interval whose lower bound starts at zero point five. Statistically it holds. But a payer reading that interval is not reading the p-value, they're reading the floor.

OK, then I'll push back on where you're putting the weight. The exercise endpoint is the one that answers you. Peak oxygen uptake moved zero point six seven milliliters per kilogram per minute in aficamten's favor, p equals zero point zero zero three — and the placebo arm was flat, essentially zero. That's not a soft instrument and it's not a control group collapsing. That's drug effect, physician-assessed, and it's the endpoint an FDA reviewer leans on when the symptom score is doing what you just described.

If it were only the symptom score, I'd be a lot more worried — so I'll take that. What the pair actually tells you is that this drug is real but modest, and the results favored aficamten consistently across the prespecified subgroups. Modest and consistent is an approval package. Modest and consistent is a much harder pricing conversation.

And that's the synthesis I'd carry into Monday. What Cytokinetics created today isn't a molecule — it's a label. The filing goes in during the fourth quarter, and the company's framing is that if approved, aficamten becomes the first cardiac myosin inhibitor covering the full spectrum of symptomatic HCM. The competitive read: one agent across obstructive and non-obstructive changes how you build a cardiology field force, and it changes what anyone holding half the spectrum can defend on price.

Which is why I'd watch the submission, not the data. Two things decide this. How narrowly the label defines who qualifies — and whether the FOREST extension throws off durability, because most of the eligible ACACIA patients rolled straight into it. Thirty-six weeks gets you approved. Two years of durability is what gets you paid, and those are different documents entirely.

Shifting to the deal side — and the biggest bet of the day is a financing, not an acquisition. Moderna priced two point six billion dollars of zero-coupon convertible notes due 2032, upsized from a planned two billion, with proceeds earmarked in part for growth in its oncology business and repayment of debt. That's a week after its personalized mRNA cancer vaccine hit in Phase 3. Let's bring in Marcus Webb on the structure.

And the counterweight to that conviction landed the same morning. BioNTech and Genentech terminated the Phase 2 of autogene cevumeran as adjuvant monotherapy in resected stage two and three colorectal cancer. The independent monitoring committee flagged a numerical imbalance in overall survival — more deaths in the vaccine arm than in observation.

More deaths in the vaccine arm. Wait — in the adjuvant setting?

In the adjuvant setting. Which is the part that should slow people down, because these are patients with no detectable disease. The combination study with immunotherapy is still running, and that distinction matters — this is a monotherapy signal, not a verdict on the modality. BioNTech dipped about seven and a half percent. Moderna raised money into the same modality on the same day.

Also on the deal side, Genentech licensed DualityBio's DUPAC payload platform — forty-five million upfront, north of a billion in milestones — to build ADCs for tumors that have already failed topo-one payloads, with Genentech carrying clinical development from here. Line those three up and today's capital-allocation lesson reads clean: the money is going toward mechanisms with a fallback — a payload you can swap out, a combination you can pivot into — and away from single-shot adjuvant monotherapy. Moderna just borrowed two point six billion dollars to buy exactly that kind of room to maneuver.

On the regulatory side — the FDA cleared Lisraya, brepocitinib, for dermatomyositis. Roivant's Priovant licensed it from Pfizer, it hits TYK2 and JAK1, and the director of the FDA's immunology and inflammation office framed it as an approved oral option for a disease that's been managed with steroids and off-label immunosuppressants. In Phase 3, about three-quarters of patients on the thirty-milligram dose reported clinically meaningful improvement in itching at a year, against thirty-three percent on placebo.

The label is the launch here.

Meaning what, specifically?

Meaning it carries the class boxed warning, and Leerink's David Risinger wrote there were no major surprises in the label and all important secondary endpoints made it in. Steroid reduction is what a rheumatologist actually prescribes toward. If that language is in the label, the boxed warning becomes a conversation. If it isn't, the boxed warning becomes the reason to wait.

Also worth noting on the regulatory front — AstraZeneca and Ionis published the full CARDIO-TTRansform results in the New England Journal today and presented them at ESC. Wainua, eplontersen, did not reduce cardiovascular events or death in TTR cardiomyopathy: twenty-nine percent on drug against thirty-two percent on placebo, in patients at a hundred and forty weeks. Stifel's Paul Matteis wrote it's hard to see a path toward filing or approval.

Why did it fail? Because AstraZeneca ran it in the wrong patients, or because the mechanism doesn't add?

That's the whole fight. Eighty-one percent of this trial was already on stabilizers, against fifty-three percent in Alnylam's HELIOS-B — so a contemporary population is exactly what AstraZeneca and Ionis enrolled, and it may be what buried eplontersen. The reading amplifying pressure on Alnylam is that the additive benefit of stacking a silencer on top of a stabilizer is smaller than HELIOS-B implied, rather than the study having been designed badly.

Alnylam is down around thirty percent since the topline landed in July.

And nucresiran is now the referendum. Its pivotal allows stabilizers, with enrollees on them. If the ceiling in this disease is the combination rather than the silencer, that stops being a next-generation readout and becomes the trial that decides whether the silencing thesis in cardiomyopathy survives at all.

Before we look ahead — Teva made a bid today that tells you exactly what distressed neuroscience is worth. Teva's international subsidiary entered a stalking-horse bid for BioXcel's dexmedetomidine sublingual film through a court-supervised Chapter 11 sale: fifty-seven and a half million dollars upfront, up to sixty-seven and a half million in contingent payments. BioXcel shares plunged sixty-six percent, to twenty-four cents.

What Teva is buying is an FDA decision eleven weeks out. The film is under review for at-home treatment of acute agitation in schizophrenia and bipolar one or two, with an action date of November fourteenth — and Teva structured directly around that risk. The contingent payments include time-based tranches tied to when approval lands, including if it slips.

An option on a launch, priced in bankruptcy court.

The thread that stays open is that a stalking horse sets the floor, not the price — the auction can go higher, and Teva collects a break fee if it loses. But the separation has already happened. The asset walks toward a November decision. The equity that paid to get it there does not walk with it.

Looking ahead — ESC in Munich runs through Monday, so more cardiology lands over the weekend. Cytokinetics files in the fourth quarter. And the BioXcel auction needs bankruptcy court approval, with November fourteenth sitting right behind it.

The thing I'd carry out of today: one positive cardiomyopathy trial with a modest delta and one clean miss, same journal, same morning. Both point at the same problem — in cardiology right now, the standard of care is improving faster than the trials built to beat it.

That's what I'll be chewing on over the weekend — how many outcomes trials are quietly enrolling against a control arm that got better after the protocol was written. Go enjoy your weekend.

And that is your Pharma Closeout for Friday, August 28th — Cytokinetics winning where nobody had won and getting marked down for it, Moderna borrowing two point six billion for oncology, BioNTech pulling a vaccine study, Lisraya approved in dermatomyositis, and Teva shopping in bankruptcy court. That is one Friday. Follow the show on Apple Podcasts, Spotify, or wherever you listen — a quick rating or share helps other listeners find us. The Week in Review lands Sunday.